The Genomic Authority Gradient: Agency, Irreversibility and Heritable Reach

My illustration entitled: “The Weight on the Pen” – A soldier signs a single sheet beside an open medical folder. Across the table, a second pen rests on a thicker stack of translucent pages. The pages reveal the outlines of his physical genetic mutations to becoming adapt underwater, each beneath the same proposed change.


This article proposes the Genomic Authority Gradient, a qualitative framework for determining how demanding the justification for a genetic intervention should be. It examines four dimensions: agency distance, constitutive depth, irreversibility and heritable reach. Each can increase the burden of justification, although the dimensions can diverge and need not yield a single ranking. The framework distinguishes the authority to consent from the grounds for acting on another person’s behalf and from the responsibility to account for effects that may reach descendants. Six worked cases apply it to adult somatic therapy, adult enhancement, childhood treatment, embryo therapy, embryo enhancement and germline editing. The argument complements existing bioethics by specifying how the scope and durability of a genetic decision change what its proponents owe to the people who will live with it.

Why genetic decisions require different kinds of justification

An adult may authorize a lasting genetic intervention because it offers relief from an illness that has shaped much of her life. Parents may request a similar change for a child whose illness cannot safely wait for a decision in adulthood. Prospective parents may seek to prevent that illness before birth through an intervention whose effects could reach descendants. The medical aim can remain recognizably similar across the three cases. The authority required to pursue it changes. The person deciding, the options available to the person affected, and the number of lives potentially implicated are different.

Genomic Sovereigntism begins with the distinction between the power to alter a genome and the authority to determine that an alteration should occur. The distinction tells us why technical feasibility, parental power, and institutional permission cannot settle the moral question on their own. The Genomic Authority Gradient addresses the next question. How much must those proposing an intervention show, and to whom must they answer, as the consequences of their decision become harder for other people to direct or escape?

Other relevant conditions being equal, the justificatory burden for genetic intervention rises as agency distance, constitutive depth, irreversibility and heritable reach increase. A stronger burden requires more than a larger body of safety evidence. Depending on the case, it may demand a better account of the decision-maker’s standing, closer scrutiny of alternatives, stronger grounds for acting before consent is possible, or arrangements that remain accountable after the original decision-makers are gone.

The four dimensions of the Genomic Authority Gradient

Dimension Question What a more demanding case requires
Agency Distance How far is the person exercising effective decision-making power from the person bearing the biological consequences? Stronger grounds for proxy authorization, earlier participation by the affected person, and scrutiny of coercion or conflicts of interest.
Constitutive Depth How extensively could the intervention shape enduring features of the person or their development? A fuller account of the intended benefit, effects across the person’s life, and the capacities or choices the intervention may enable or constrain.
Irreversibility How realistically could the person later stop, reverse or mitigate the effects, or escape dependencies created by the intervention? Stronger reasons for acting now, comparison with less enduring alternatives, and credible plans for continued care and redress.
Heritable Reach Could changed biological material be transmitted to descendants, and what effects might they inherit? Reasons that extend beyond the immediate patient or family, explicit treatment of uncertainty across generations, and oversight that can endure.

Agency distance concerns who effectively decides. An adult who asks a physician to perform a procedure can retain first-person authority over the decision. A parent who authorizes treatment for a child exercises custodial authority grounded in the child’s welfare. An employer who makes a procedure a condition of promotion can acquire practical influence over a decision formally recorded as the employee’s. Agency distance can therefore increase even where the affected person has decision-making capacity. The assessment must ask whether their refusal is effective and whether another party can determine what refusal will cost.

Constitutive depth concerns the scope of the intervention in a person’s development and life. A change affecting a specific biological function may have a profound effect if it changes whether someone can remain well, learn or take part in ordinary activities. The number of sites altered in a genome cannot by itself tell us how deep the effects will be. Depth can also count in favour of an intervention. Preventing a severe developmental harm may substantially expand future agency. Because large consequences run in both directions, proponents must explain what the intervention is expected to make possible and what it may foreclose.

Irreversibility concerns what the person can actually do after the decision. Biological reversal, mitigation of an adverse effect and freedom to leave a treatment relationship are distinct possibilities. A person may be unable to reverse a change while remaining free to change clinicians or decline participation in research. Conversely, an intervention described as reversible may leave someone practically dependent if reversal is unsafe, expensive or available from only one provider. Ending permission for future procedures is a meaningful exercise of agency even after an earlier change has become permanent.

Heritable reach concerns biological transmission. A nonheritable intervention can affect a family’s life profoundly through caregiving, financial demands or changes in the patient’s health. Those consequences matter in their own right. Heritability adds a distinct question about descendants who may receive the change in their own bodies. An assessment should distinguish the possibility of transmission, the evidence about its likelihood, and the consequences if it occurs. An uncertain route of transmission calls for an explicit assessment of that uncertainty.

How to apply the gradient

Begin by identifying the proposed intervention, its objective, who can authorize or refuse it, and who could bear its effects. State the comparison explicitly. Depending on the case, it may be ordinary care, a less enduring intervention, a treatment confined to the patient, or waiting until the affected person can decide. The consequences of waiting belong in the analysis. For a child with progressive disease, delay may itself irreversibly remove capacities that a timely intervention could preserve.

Next describe each dimension separately and identify what the evidence leaves uncertain. A proposal becomes harder to justify on the gradient when it makes at least one dimension more demanding while leaving the others comparable. When the dimensions move in different directions, there may be no determinate ranking. An adult’s informed request for a permanent change and a surrogate’s request for a temporary intervention for a child raise different demands. The comparison is useful because it identifies the reasons each decision needs, even when they cannot be put in a single order.

Finally, identify what would satisfy each demand and who is responsible for doing so. Valid consent addresses whether a competent adult authorizes a change to their body. The clinician still needs adequate grounds to offer it. Evidence of benefit to one child addresses an important part of the case for a proposed intervention. It leaves heritable effects and any risks to descendants to be justified. These obligations cannot be added into a score or traded away through a favourable result on another dimension. A decision record should state the grounds for proceeding, deferring or declining and describe what new evidence or change in circumstances could alter that conclusion.

Six worked cases

1. Adult somatic therapy for serious disease

Consider a competent adult researching treatment for sickle cell disease with recurrent vaso-occlusive crises. In December 2023, the US Food and Drug Administration approved Casgevy for patients aged 12 and older with sickle cell disease and recurrent crises. Its approval provides a real example of a somatic genome-editing treatment. The case here concerns an adult who can deliberate and decide voluntarily. The intended change is in the patient’s blood-forming cells, with no intended transmission to descendants. The consequences may be substantial for the patient and the intervention is not readily undone. [1]

Agency distance is short in this case, while the demands of irreversibility remain substantial. The justification rests on a meaningful expected clinical benefit, an assessment of the intervention and alternatives for that individual, and a consent process that addresses risks and follow-up. If a different provider could not readily take over later care, that practical dependency would deserve separate attention. The patient’s decision establishes authority to proceed on their behalf, subject to the clinician’s independent judgment that treatment can responsibly be offered.

2. Adult enhancement under employment pressure

Suppose a future clinic offers an adult a durable, nonheritable intervention intended to improve endurance. The adult already meets the requirements of her job, but her employer starts reserving better assignments for workers who undergo the procedure. Her signature may reflect a reasoned desire to accept the intervention. It may also reflect the prospect of losing career opportunities. The employer’s control over those opportunities lengthens effective agency distance, even though the decision is legally recorded as hers.

Holding biological depth and irreversibility constant, removing the employer’s condition would improve the grounds for calling the decision voluntary. The intervention would still require reliable evidence and a proportionate clinical justification. A modest elective benefit can support accepting fewer uncertain burdens than relief from a serious disease would support. The case shows how two people considering the same intervention can face different questions of authority because different parties control the consequences of refusal.

3. Childhood treatment before a window closes

Imagine a child with a progressive inherited condition and a hypothetical somatic treatment with credible evidence of benefit. Waiting until adulthood would likely allow serious, lasting loss of function. The parents’ permission increases agency distance because the person deciding and the person bearing the effects are different. The expected benefit may be deep, the change difficult to reverse, and the biological effects confined to the child. The American Academy of Pediatrics’ guidance on parental permission and childhood assent supports progressively involving the child as their capacities develop. [2]

Here the stronger burden can be met in principle. The reason to act is that timely care could preserve abilities the child would otherwise lose. The decision should explain why waiting or using a less enduring treatment would offer materially less protection. It should also involve the child in choices they can understand and preserve later control over matters such as optional follow-up research. If temporary care could safely protect the same abilities until the child can decide, the case for authorizing the permanent option now would weaken.

4. Embryo therapy for a serious inherited condition

Suppose prospective parents propose modifying an embryo intended for transfer to prevent a severe early-onset genetic disease. The medical aim centres on the welfare of the child who may be born. The affected person is unable to participate, the change may shape development from an early stage, and reversal should not be assumed. If the effects could be inherited, the proposal must be assessed on that basis. A therapeutic aim establishes the kind of benefit sought. It does not determine the biological reach of the intervention.

The strongest version of the case would explain why the expected benefit is substantial, why available alternatives offer materially less protection, and how to account for the risks to both the first child and possible descendants. The 2020 international commission distinguished potentially defensible future applications for serious single-gene disease from the evidence needed before an edited embryo could be used to establish a pregnancy. The organizing committee of the Third International Summit on Human Genome Editing concluded in 2023 that the necessary conditions for heritable clinical use had yet to be met. The moral seriousness of the aim makes the proposal worth evaluating. It supplies no shortcut past an unmet evidentiary threshold. [3, 4]


My illustration “The Weight on the Pen” work-in-progress, inspired by ‘Aquaman’. The art represents that a signature carries greater moral weight when it may permanently reshape the body of the person who signs it.


5. Embryo enhancement for a preferred capacity

Now imagine a request to edit an embryo to increase a future child’s prospects in competitive sport. Assume for the comparison that an effect could be established. The future child cannot decide, the change could shape enduring capacities, and it may be difficult to reverse or potentially heritable. The benefit is more dependent on a particular conception of success than relief from severe early-onset illness. It may prove less valuable if the child chooses a life in which the enhanced capacity matters little.

The parents’ reason for acting must be assessed against the child’s ability to pursue that capacity later through means they can choose or decline. The assessment also has to consider what happens if institutions come to treat the enhancement as a condition for ordinary opportunity. The Nuffield Council on Bioethics places the welfare of the future person alongside concerns about disadvantage, discrimination and social division. On the facts given here, the expected advantage supplies too weak a justification for a lasting decision made for the child, especially where safer and more voluntary ways to develop the capacity remain available. [5]

6. Germline editing intended to prevent transmission across generations

Suppose two hypothetical approaches could offer a future child comparable protection from a serious disease. One is confined to the child. The other could also prevent transmission of the disease-associated change through the family line. This case overlaps with embryo therapy because a therapeutic intervention can also be heritable. Its distinctive question is whether an anticipated benefit to descendants warrants choosing a route with broader reach when the immediate child could be comparably protected without it.

The multigenerational benefit deserves consideration, especially if descendants could otherwise face severe disease and lack reasonable options. The proposal still needs evidence supporting that benefit, an account of which people could inherit unintended burdens, and a reason why a decision made now is preferable to leaving later people further opportunities to act. As stipulated, comparable protection for the child removes one important ground for accepting the additional heritable exposure. If the broader case could someday be made, it would still require arrangements for independent oversight, access to care and follow-up that respects the choices of people born after the original authorization. [3, 6]

Relationship to existing bioethics

The gradient operates alongside established principles of biomedical ethics. Beauchamp and Childress’s account gives distinct attention to autonomy, nonmaleficence, beneficence and justice. The gradient asks how the organization of a genomic decision changes what those considerations require in practice. A competent adult’s authorization supplies reasons of one kind. Proxy authorization requires reasons grounded in the affected person’s interests. Heritable exposure introduces people for whom neither of those decisions can speak completely. The framework identifies where the justificatory work lies without assigning a fixed priority to the underlying bioethical principles. [7]

It also draws on paediatric ethics and existing work on future-person welfare and genome-editing governance. Paediatric ethics helps explain why permission and assent have different roles. The Nuffield report shows why welfare and the social distribution of disadvantage must enter the assessment together. The international commission and WHO address evidentiary thresholds and institutional oversight. The contribution of the gradient is to connect those inquiries through the authority question. For any proposal, it asks who can legitimately make each decision, how far the consequences extend, and what becomes harder to justify as the affected person’s practical control diminishes. [2, 3, 5, 6]

Limitations

The gradient is a conceptual framework. It cannot establish the probability of a clinical outcome, decide the legal status of a procedure, or determine what a healthcare system should fund. A favourable assessment of a person’s authority to consent leaves clinical safety and justice to be evaluated. A demanding assessment also leaves open the possibility that urgent need, strong evidence and the absence of adequate alternatives together justify proceeding. Explicitly stating those conditions makes the judgment easier to examine later.

The dimensions can interact. An early intervention may shape development and be difficult to reverse, while the same clinical evidence bears on both judgments. Repeating a concern under two headings gives it no additional force. Uncertainty may also persist about who will be affected or how an effect will be expressed. The review should record where a conclusion depends on an assumption, consider how plausible alternatives would change it, and revisit that conclusion when better evidence becomes available.

Finally, assessments of depth and welfare can reflect assumptions about disability, social participation and desirable traits. A change can look more beneficial to a reviewer who takes existing barriers for granted. People with lived experience may identify possibilities for care, accommodation or participation that would alter the comparison. The gradient can make these disagreements visible, but their resolution requires evidence, the perspectives of affected communities and a willingness to revise the assessment.

Conclusion

The burden of justifying a genetic intervention depends on the relationship between those who decide and those who live with the decision. An intervention can be permanent and still fall within a competent adult’s authority to accept. Early treatment can protect the future agency of a child who cannot yet consent. A heritable intervention can reach people for whom present authorization provides only part of the justification. The Genomic Authority Gradient makes those differences explicit and asks decision-makers to give reasons commensurate with the power they propose to exercise.

References

  1. US Food and Drug Administration. (2023, December 8). FDA approves first gene therapies to treat patients with sickle cell disease.
  2. American Academy of Pediatrics, Committee on Bioethics. (2016). Informed consent in decision-making in pediatric practice. Pediatrics, 138(2), e20161484.
  3. National Academy of Medicine, National Academy of Sciences, and the Royal Society. (2020). Heritable Human Genome Editing. The National Academies Press.
  4. Organising Committee of the Third International Summit on Human Genome Editing. (2023). Statement from the Organising Committee of the Third International Summit on Human Genome Editing. Royal Society.
  5. Nuffield Council on Bioethics. (2018). Genome Editing and Human Reproduction: Social and Ethical Issues.
  6. World Health Organization. (2021). Human Genome Editing: Recommendations.
  7. Beauchamp, T. L., & Childress, J. F. (2019). Principles of Biomedical Ethics (8th ed.). Oxford University Press.